Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Positive symbols : LLY save search
Giant-Cell Arteritis Market to Showcase Positive Growth at a CAGR of 9.3% by 2034 | DelveInsight
Published: 2024-04-08 (Crawled : 22:00) - prnewswire.com
JNJ | News | $150.09 0.65% 3.9M
|
Health Technology
|
| O: -0.3%
H: 0.0%
C: 0.0%
LLY | News | $741.37 1.37% 800K
|
Health Technology
|
| O: 0.05%
H: 0.02%
C: -2.62%
MOR | News | $18.01 0.28% 130K
|
Health Technology
|
| O: 0.06%
H: 0.22%
C: 0.0%
KNSA | $17.99 5.24% 270K
|
Health Technology
|
| O: 0.23%
H: 1.58%
C: 0.06%
IMAB | $1.825 1.39% 110K
|
Health Technology
|
| O: -0.55%
H: 1.39%
C: 0.0%
GLPG | News | $29.695 2.15% 69K
|
Health Technology
|
| O: 0.0%
H: 0.39%
C: -0.66%
positive growth market
REVALESIO ANNOUNCES POSITIVE TOPLINE DATA FROM PHASE 2 RESCUE STUDY OF RNS60 IN PATIENTS WITH ACUTE ISCHEMIC STROKE IN LATE-BREAKING ORAL PRESENTATION AT ISC 2024
Published: 2024-02-07 (Crawled : 23:00) - biospace.com/
LLY | News | $741.37 1.37% 800K
|
Health Technology
|
| O: 0.76%
H: 4.31%
C: 2.11%
rns60 stroke presentation positive topline study
Positive Phase 1/2 Clinical Trial Data for an Investigational Gene Therapy for Genetic Hearing Loss to be Presented at the Association for Research in Otolaryngology 2024 MidWinter Meeting
Published: 2024-01-23 (Crawled : 17:00) - prnewswire.com
LLY | News | $741.37 1.37% 800K
|
Health Technology
|
| O: -0.51%
H: 0.37%
C: 0.32%
genetic association positive research meeting trial therapy
Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer
Published: 2023-12-18 (Crawled : 12:30) - globenewswire.com
PNT | $13.68 2.63% 0.15% 0
|
|
| O: -10.09%
H: 0.0%
C: 0.0%
LLY | News | $741.37 1.37% 800K
|
Health Technology
|
| O: 1.61%
H: 1.14%
C: 0.57%
LNTH | $65.22 3.41% 200K
|
Health Technology
|
| O: -19.87%
H: 5.04%
C: -8.75%
positive cancer biopharma topline trial results
Metastatic Prostate Cancer Market to Exhibit Positive Growth at a CAGR of 22% and 7.5% for mHSPC and mCRPC, respectively During the Study Period (2019-2032), Assesses DelveInsight
Published: 2023-12-13 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 0.25%
H: 0.0%
C: 0.0%
LLY | News | $741.37 1.37% 800K
|
Health Technology
|
| O: 1.8%
H: 0.0%
C: 0.0%
SNY | News | $47.85 1.49% 920K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
positive cancer growth study market
ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
Published: 2023-10-03 (Crawled : 10:00) - globenewswire.com
LLY | News | $741.37 1.37% 800K
|
Health Technology
|
| O: 0.19%
H: 0.0%
C: 0.0%
ALXO M | $15.165 6.57% 140K
|
Commercial Services
|
| O: 68.19%
H: 2.84%
C: -7.17%
aspen-06 positive cancer treatment trial results
Alopecia Areata Market to Show Positive Growth at a CAGR of 26.3% During the Study Period (2019-2032), Estimates DelveInsight
Published: 2023-06-19 (Crawled : 20:00) - prnewswire.com
LLY | News | $741.37 1.37% 800K
|
Health Technology
|
| O: -0.41%
H: 2.02%
C: 1.37%
SNY | News | $47.85 1.49% 920K
|
Health Technology
|
| O: 1.71%
H: 0.0%
C: 0.0%
INCY | $51.81 -0.21% 890K
|
Health Technology
|
| O: 0.3%
H: 0.17%
C: -2.63%
positive show growth study market
AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial
Published: 2023-01-26 (Crawled : 12:20) - globenewswire.com
LLY | News | $741.37 1.37% 800K
|
Health Technology
|
| O: 0.36%
H: 0.34%
C: -0.85%
ACIU | $2.435 0.62% 82K
|
Health Technology
|
| O: 10.68%
H: 0.0%
C: -7.34%
aci-24 vaccine trial alzheimer’s positive aci-24.060 anti-amyloid beta phase 2b
Lilly Shares Positive Donanemab Data in First Active Comparator Study in Early Symptomatic Alzheimer's Disease
Published: 2022-11-30 (Crawled : 00:00) - prnewswire.com
LLY | News | $741.37 1.37% 800K
|
Health Technology
|
| O: 1.0%
H: 0.11%
C: -1.19%
disease active alzheimer's positive study
HUTCHMED Announces Positive Topline Result in Fruquintinib Phase III FRUTIGA Study in Second-Line Gastric Cancer in China
Published: 2022-11-14 (Crawled : 00:00) - hutch-med.com
LLY | News | $741.37 1.37% 800K
|
Health Technology
|
| O: 1.92%
H: 0.48%
C: -0.84%
BGNE | $138.615 5.86% 110K
|
Health Technology
|
| O: 3.05%
H: 1.74%
C: -0.5%
topline china positive cancer study
Veru Announces Presentation of Final Positive Phase 1b/2 Clinical Trial Results for Sabizabulin in Metastatic Castration Resistant Prostate Cancer at the 2022 American Society of Clinical Oncology Annual Meeting
Published: 2022-06-06 (Crawled : 11:00) - globenewswire.com
LLY | News | $741.37 1.37% 800K
|
Health Technology
|
| O: 3.83%
H: 0.0%
C: 0.0%
VERU | $1.415 11.42% 1.4M
|
Health Technology
|
| O: 10.2%
H: 0.0%
C: 0.0%
sabizabulin trial presentation positive cancer phase 2b prostate cancer
FDA States that Veru Should Submit Request for Emergency Use Authorization (EUA) Based on Positive Efficacy and Safety Data from the Phase 3 Clinical Study of Sabizabulin in Hospitalized COVID-19 Patients
Published: 2022-05-11 (Crawled : 11:00) - biospace.com/
LLY | News | $741.37 1.37% 800K
|
Health Technology
|
| O: -3.03%
H: 0.0%
C: 0.0%
VERU | $1.415 11.42% 1.4M
|
Health Technology
|
| O: 20.75%
H: 0.0%
C: 0.0%
covid-19 fda sabizabulin authorization positive phase 3 emergency use authorization
FDA Has Granted Veru a Pre-Emergency Use Authorization (EUA) Meeting Date for Positive Sabizabulin Phase 3 COVID-19 Study
Published: 2022-05-02 (Crawled : 13:20) - biospace.com/
LLY | News | $741.37 1.37% 800K
|
Health Technology
|
| O: -0.92%
H: 0.0%
C: 0.0%
VERU | $1.415 11.42% 1.4M
|
Health Technology
|
| O: 8.28%
H: 2.44%
C: -19.07%
covid-19 fda sabizabulin granted authorization positive phase 3 emergency use authorization
Lilly, BI-Partnered Kidney Trial Stopped Early Due to Positive Results
Published: 2022-03-16 (Crawled : 17:00) - biospace.com/
LLY | News | $741.37 1.37% 800K
|
Health Technology
|
| O: 0.87%
H: 0.27%
C: -0.51%
pos kidney trial positive results positive results
Jardiance® phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease
Published: 2022-03-16 (Crawled : 14:00) - biospace.com/
LLY | News | $741.37 1.37% 800K
|
Health Technology
|
| O: 0.87%
H: 0.27%
C: -0.51%
jardiance pos kidney trial disease positive
AnHeart Therapeutics and Innovent Biologics Receive NMPA Breakthrough Designation for Taletrectinib in ROS1 Fusion-Positive Non-Small Cell Lung Cancer
Published: 2022-03-01 (Crawled : 15:00) - biospace.com/
LLY | News | $741.37 1.37% 800K
|
Health Technology
|
| O: 1.26%
H: 0.0%
C: 0.0%
INCY | $51.81 -0.21% 890K
|
Health Technology
|
| O: 0.44%
H: 2.1%
C: 0.88%
heart therapeutics cel lung cancer positive cancer designation
Innovent Biologics and AnHeart Therapeutics Receive NMPA Breakthrough Designation for Taletrectinib in ROS1-Positive Non-Small Cell Lung Cancer
Published: 2022-03-01 (Crawled : 02:00) - prnewswire.com
LLY | News | $741.37 1.37% 800K
|
Health Technology
|
| O: 1.26%
H: 0.0%
C: 0.0%
INCY | $51.81 -0.21% 890K
|
Health Technology
|
| O: 0.44%
H: 2.1%
C: 0.88%
heart therapeutics cel lung cancer positive cancer designation
FDA Expands Lilly's ERBITUX® (cetuximab) Label with Combination of BRAFTOVI® (encorafenib) for the Treatment of BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC) after Prior Therapy
Published: 2021-09-28 (Crawled : 22:00) - prnewswire.com
PFE | News A | $26.24 -0.08% 11M
|
Health Technology
|
| O: 0.42%
H: 1.09%
C: 0.72%
LLY | News | $741.37 1.37% 800K
|
Health Technology
|
| O: 1.72%
H: 2.68%
C: 2.2%
treatment fda positive therapy cancer colorectal cancer
AnHeart and Innovent Announce Interim Data from Phase Ⅱ Trial (TRUST) of Taletrectinib in ROS1-Positive NSCLC at the CSCO 2021 Annual Meeting
Published: 2021-09-27 (Crawled : 13:00) - biospace.com/
LLY | News | $741.37 1.37% 800K
|
Health Technology
|
| O: -1.21%
H: 0.47%
C: -1.55%
heart positive trial
Innovent and AnHeart Announce Interim Data from Phase 2 Trial of Taletrectinib in ROS1-Positive NSCLC at the CSCO 2021 Annual Meeting
Published: 2021-09-27 (Crawled : 00:00) - prnewswire.com
LLY | News | $741.37 1.37% 800K
|
Health Technology
|
| O: -1.21%
H: 0.47%
C: -1.55%
INCY | $51.81 -0.21% 890K
|
Health Technology
|
| O: -0.89%
H: 0.54%
C: 0.51%
phase 2 heart positive trial
Gainers vs Losers
| 87% | 13% |
Top 10 Gainers
MTTR | News M | $4.64 166.67% 18M
|
AGBA | $2.61 108.8% 41M
|
Finance
CZOO | $9.32 86.77% 18M
|
EDBL | News | $6.7 78.19% 1.7M
|
OPRT | News | $3.37 49.78% 8.9M
|
Finance
MTC | $2.14 37.18% 4.9M
|
Technology Services
VNRX | $0.8 33.33% 2.9M
|
Health Technology
MLEC | $1.79 27.86% 2.6M
|
n/a
PALI | $6.29 27.59% 22M
|
Manufacturing
MCRB | $0.7902 26.51% 6.9M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.